Generic Bepreve Availability
BEPREVE (bepotastine besilate - solution/drops;ophthalmic)
Manufacturer: BAUSCH AND LOMB INC
Approval date: September 8, 2009
Strength(s): 1.5% [RLD]
Has a generic version of Bepreve been approved?
No. There is currently no therapeutically equivalent version of Bepreve available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bepreve. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Acid addition salt of optically active piperidine compound and process for preparing the same
Issued: August 24, 2004
Inventor(s): Jun-ichiro; Kita & Hiroshi; Fujiwara & Shinji; Takamura
Assignee(s): Ube Industries, Ltd. Tanabe Seiyaku Co., Ltd.
The present invention is to provide a benzenesulfonic acid salt and a benzoic acid salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid represented by the formula (I): wherein * represents an asymmetric carbon, which are excellent in antihistaminic activity and anti-allergic activity, and a process for producing the same.Patent expiration dates:
- September 19, 2019✓✓
- September 19, 2019
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 8, 2014 -
- Bepreve Consumer Information (Drugs.com)
- Bepreve eye drops Consumer Information (Wolters Kluwer)
- Bepreve Consumer Information (Cerner Multum)
- Bepreve Advanced Consumer Information (Micromedex®)
- Bepreve AHFS DI Monographs (ASHP)
- Bepotastine eye drops Consumer Information (Wolters Kluwer)
- Bepotastine ophthalmic Consumer Information (Cerner Multum)
- Bepotastine besilate Ophthalmic Advanced Consumer Information (Micromedex®)
- Bepotastine Besilate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|